Key takeaways
- ~$300K approximate annual cost of intravenous enzyme replacement therapy per Gaucher patient · Boston Globe 2014 / payer policy
- $310,250 eliglustat (Cerdelga) launch annual WAC — oral, routes to Medicare Part D · Boston Globe 2014
- Part B vs D IV ERT routes to the Part B medical benefit (buy-and-bill); oral SRT routes to the Part D pharmacy benefit · CMS
Gaucher type 1 splits payer economics by route: IV enzyme replacement routes to Part B buy-and-bill at ~$300K a year, while oral therapies route to Part D — and the CYP2D6 gate plus generic miglustat reshape utilization management.
The three enzyme replacement therapies, imiglucerase (Cerezyme), velaglucerase alfa (VPRIV), and taliglucerase alfa (Elelyso), are physician-administered intravenous infusions and route through the Medicare Part B medical benefit under buy-and-bill, not Part D. Annual ERT cost is approximately $300,000 per patient, placing Gaucher among the highest-cost chronic therapies in US medicine. Commercial payers cover all three as medically necessary for confirmed type 1 disease (enzyme deficiency or biallelic GBA1 variant plus anemia, thrombocytopenia, organomegaly, or bone disease), and several designate imiglucerase and velaglucerase as preferred, positioning taliglucerase as a non-preferred alternative.
The oral substrate reduction therapies route differently. Eliglustat (Cerdelga) launched in 2014 at an annual WAC of $310,250 and dispenses through the Part D pharmacy benefit; its prior authorization requires a diagnosis of type 1 plus documented CYP2D6 extensive, intermediate, or poor metabolizer status by an FDA-cleared test — a genotype gate that functions as a built-in utilization-management lever. Miglustat (Zavesca) is reimbursed narrowly, for mild-to-moderate patients for whom ERT is not an option, and payers increasingly require a trial of generic miglustat first. The net payer picture is a mature orphan market where cost control comes through channel routing, step edits, preferred-ERT designation, and generic substitution rather than head-to-head price competition.
US Gaucher type 1 agent payer status — routing, cost and PA
| Drug (Brand / INN) | Mechanism / Route | Benefit Routing | Approx. Annual Cost | PA Criteria (Commercial) |
|---|---|---|---|---|
| Cerezyme (imiglucerase) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Confirmed type 1 (enzyme or biallelic GBA1) + anemia / thrombocytopenia / organomegaly / bone disease; often preferred ERT |
| VPRIV (velaglucerase alfa) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Same clinical criteria; frequently designated preferred ERT |
| Elelyso (taliglucerase alfa) | IV enzyme replacement | Medicare Part B (buy-and-bill) | ~$300,000 | Same clinical criteria; typically non-preferred alternative |
| Cerdelga (eliglustat) | Oral substrate reduction | Medicare Part D | $310,250 | Type 1 + CYP2D6 extensive / intermediate / poor metabolizer by FDA-cleared test |
| Zavesca (miglustat) | Oral substrate reduction | Medicare Part D | Generic available | Mild–moderate type 1 when ERT not an option; generic miglustat trial often required |
Sources: UnitedHealthcare and Blue Cross Blue Shield Gaucher ERT medical coverage policies (2025–2026); Cerdelga launch WAC per Boston Globe 2014; FDA prescribing information (Cerdelga, Zavesca); FDA Drugs@FDA.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How do IV enzyme replacement therapy (Part B buy-and-bill) and oral substrate reduction therapy (Part D) differ in benefit routing, site of care and patient out-of-pocket burden? • Part B vs Part D benefit-category split • buy-and-bill vs pharmacy dispensing • site-of-care and OOP implications for IV vs oral therapy
- What prior-authorization and utilization-management criteria, including the CYP2D6 gate for eliglustat and generic-first requirements for miglustat, govern access at major US payers? • Commercial PA criteria for ERT and SRT • the CYP2D6 metabolizer requirement for eliglustat • ERT-not-an-option and generic-miglustat-first requirements for miglustat
- How do preferred-ERT designation, generic miglustat and orphan pricing shape cost control across the Gaucher type 1 market? • Preferred vs non-preferred ERT designation • generic miglustat's low-end anchor • orphan pricing dynamics and the main payer cost-control levers
What's inside
-
1 · US Payer Landscape — Gaucher Coverage Architecture 4 pp
- All three IV enzyme replacement therapies route through Medicare Part B under buy-and-bill, while oral agents dispense through Part D
- Commercial payers cover ERT as medically necessary for confirmed type 1 disease: enzyme deficiency or biallelic GBA1 variant plus anemia, thrombocytopenia, organomegaly or bone disease
-
2 · Part B vs Part D — Routing, Site of Care & OOP 5 pp
- IV enzyme replacement therapies route to the Part B medical benefit (buy-and-bill) while eliglustat and miglustat route to the Part D pharmacy benefit
- Eliglustat launched in 2014 at an annual WAC of $310,250 dispensed through Part D, a distinct site-of-care and OOP profile from the infused ERTs
-
3 · Enzyme Replacement Buy-and-Bill Economics 4 pp
- Annual ERT cost runs approximately $300,000 per patient, placing Gaucher among the highest-cost chronic therapies in US medicine
- Several payers designate imiglucerase and velaglucerase alfa as preferred ERT, positioning taliglucerase alfa as the non-preferred alternative
-
4 · Commercial Payer PA & Utilization Management 5 pp
- Prior authorization for ERT requires confirmed type 1 diagnosis by enzyme assay or biallelic GBA1 variant, plus anemia, thrombocytopenia, organomegaly or bone disease
- Utilization management differs sharply between the three medically-necessary ERTs and eliglustat's genotype-gated, Part D prior-authorization pathway
-
5 · The CYP2D6 Gate & Generic Miglustat Dynamics 4 pp
- Eliglustat's prior authorization requires documented CYP2D6 extensive, intermediate or poor metabolizer status by an FDA-cleared test, a genotype gate that functions as built-in utilization management
- Payers increasingly require a trial of generic miglustat before considering other options for mild-to-moderate patients where ERT is not appropriate
-
6 · Orphan Pricing & Cost-Control Levers 3 pp
- Cost control in this mature orphan market comes through channel routing, step edits and preferred-ERT designation rather than head-to-head price competition
- Generic miglustat substitution is the market's primary price-competition lever, since none of the three branded ERTs face generic entry
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Gaucher Payer & HTA is built for market access, HEOR, and pricing teams navigating Part B/D routing, PA criteria, and the oral-versus-IV cost picture in the US Gaucher market. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (routing, PA criteria), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, cost data, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Gaucher Payer & HTA sources: CMS Part B vs Part D benefit-category rules, UnitedHealthcare and Blue Cross Blue Shield Gaucher ERT medical coverage policies (2025–2026), the Cerdelga and Zavesca FDA prescribing information, and contemporaneous WAC reporting (Boston Globe 2014).
- Part B vs Part D routing verified against CMS benefit-category rules for physician-administered infusions vs oral agents and payer medical/pharmacy policies
- Commercial PA criteria and preferred-ERT designation verified against UnitedHealthcare and Blue Cross Blue Shield Gaucher coverage policies (2025–2026)
- Eliglustat CYP2D6 prior-authorization gate verified against the Cerdelga FDA prescribing information and payer policy
- Eliglustat launch WAC ($310,250) verified against contemporaneous reporting (Boston Globe 2014)
Frequently asked questions
Access Why does benefit routing matter for Gaucher disease therapies?
The three intravenous enzyme replacement therapies are physician-administered and route through the Medicare Part B medical benefit under buy-and-bill, at roughly $300,000 per patient per year. The oral substrate reduction therapies, eliglustat and miglustat, route through the Part D pharmacy benefit instead. This split drives different site-of-care economics, prior-authorization pathways and patient out-of-pocket structures for otherwise interchangeable-intent therapies.
Utilization What controls access to eliglustat and miglustat?
Eliglustat's prior authorization requires a Gaucher type 1 diagnosis plus documented CYP2D6 extensive, intermediate or poor metabolizer status by an FDA-cleared test — a genotype gate absent from enzyme replacement therapy. Miglustat is reimbursed only for mild-to-moderate patients for whom ERT is not an option, and payers increasingly require a trial of generic miglustat first, anchoring the low-cost end of the oral market.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck. An optional 60-minute analyst readout call is included with all deliveries.